

Elazar Rabbani et al.

Serial No. 08/978,635

Filed: November 25, 1997

Page 2 (Amendment In Connection With Notice To Comply With Sequence Rules -
June 8, 1998)

REMARKS

By this Amendment applicants are directing the entry of the initial paper copy of the accompanying "Sequence Listing" into the instant specification, thereby conforming with one of the requirements of the Notice To Comply With Sequence Listing.

No fee is believed due in connection with this Amendment. If any fee or fees are due, however, the Patent and Trademark Office is hereby authorized to charge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto.

If helpful to processing this Amendment, the undersigned may be contacted by telephone at (212) 583-0100 during the daytime hours.

Respectfully submitted,



Ronald C. Fedus
Registration No. 32,567
Attorney for Applicants

ENZO THERAPEUTICS, INC.
c/o Enzo Biochem, Inc.
527 Madison Avenue (9th Fl.)
New York, New York 10022
(212) 583-0100


LC/USProsecution/Enz53\enz53(d4)\amendmentresequencerules 060898 3enz53D4

ENZ-53(D4)

Elazar Rabbani et al.
Serial No.: 08/574,443
Filed: Herewith
Page: 4 (Request for a Continuation Application Under 37 C.F.R. 1.60 -
November 25, 1997)

Code and that such willful false statements may jeopardize the validity of the
application or any patent issuing thereon.

Nov 25 97
Date



Signature [Ronald C. Fedus]
Registration No. 32, 567
Attorney for Applicants

Inventor(s)

Assignee of Complete Interest
☒ X
Attorney or Agent of Record

Filed under 37 CFR 1.34(a)

Address of Signator:
Enzo Therapeutics, Inc.
c/o Enzo Biochem, Inc.
527 madison Avenue (9th Floor)
New York, New York 10022